GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (FRA:9ZT1) » Definitions » Quick Ratio

Alzamend Neuro (FRA:9ZT1) Quick Ratio : 0.16 (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Alzamend Neuro's quick ratio for the quarter that ended in Jan. 2024 was 0.16.

Alzamend Neuro has a quick ratio of 0.16. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Alzamend Neuro's Quick Ratio or its related term are showing as below:

FRA:9ZT1' s Quick Ratio Range Over the Past 10 Years
Min: 0.16   Med: 3.19   Max: 26.61
Current: 0.16

During the past 5 years, Alzamend Neuro's highest Quick Ratio was 26.61. The lowest was 0.16. And the median was 3.19.

FRA:9ZT1's Quick Ratio is ranked worse than
94.94% of 1543 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:9ZT1: 0.16

Alzamend Neuro Quick Ratio Historical Data

The historical data trend for Alzamend Neuro's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Quick Ratio Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23
Quick Ratio
1.27 1.83 3.24 12.37 2.03

Alzamend Neuro Quarterly Data
Apr19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.19 2.03 0.88 0.21 0.16

Competitive Comparison of Alzamend Neuro's Quick Ratio

For the Biotechnology subindustry, Alzamend Neuro's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzamend Neuro's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Quick Ratio falls into.



Alzamend Neuro Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Alzamend Neuro's Quick Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Quick Ratio (A: Apr. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5.322-0)/2.617
=2.03

Alzamend Neuro's Quick Ratio for the quarter that ended in Jan. 2024 is calculated as

Quick Ratio (Q: Jan. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.545-0)/3.512
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzamend Neuro  (FRA:9ZT1) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Alzamend Neuro Quick Ratio Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzamend Neuro (FRA:9ZT1) Business Description

Traded in Other Exchanges
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro (FRA:9ZT1) Headlines

No Headlines